Pharmacokinetic Effects of Oral DMAA

University of Memphis logo

University of Memphis

Status

Completed

Conditions

Outcomes of Single Oral Dose

Treatments

Dietary Supplement: DMAA

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01765933
DMAA Pharmacokinetics

Details and patient eligibility

About

1,3-dimethylamylamine (DMAA) has become increasingly popular as a component of dietary supplements. It is also used within "party pills," often in conjunction with alcohol and other drugs, and has been associated with untoward effects when abused at high dosages. To our knowledge, no studies have been conducted to determine the combined pharmacokinetic profile and physiologic responses of DMAA. To conclude on the safety profile of DMAA based solely on case reports would be problematic, in particular when accepting testimony from patients in uncontrolled environment, potentially under the influence of alcohol and other drugs. This is especially true in light of the fact that no prospective studies have shown these effects. Hence, the intent of the present study was to determine the pharmacokinetic profile of a single 25mg oral dosage of DMAA alone through 24 hours post-ingestion. This represents a typical dosage within one serving of many popular dietary supplements containing DMAA.

Enrollment

8 patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • must be able to swallow pill

Exclusion criteria

  • self-reported cardiovascular or metabolic problems
  • current smokers

Trial design

8 participants in 1 patient group

DMAA
Experimental group
Description:
Single oral dose 25 mg DMAA
Treatment:
Dietary Supplement: DMAA

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems